Sprout BioVentures invests in early-stage opportunities to translate key insights in human biology into viable therapeutics. We firmly believe that no target is "undruggable" - rather, it is currently "undone". We are ready to share our expertise in developing comprehensive chemical equity strategies and will do "whatever it takes" to identify high-quality candidates for clinical proof-of-concept.
We are excited by new technology platforms transforming our ability to manipulate biology. However, this is not our focus. We are drawn to the compelling targets which have emerged from population-wide genetic association studies, where human loss-of-function mutations point to an inhibitor strategy, and gain-of-function mutations provide a gene dose-response. We believe pursuit of these targets will have a higher likelihood of clinical success - and here's our data to back that up.
Brian Hubbard has over 20 years of experience in the biopharmaceutical industry. He has directed research and development efforts at Millenium Pharmaceuticals, Novartis, and Merck, and recently built an industry-facing group at the Broad Institute. He has a proven track record of delivering therapies to the clinic and has founded several biotechnology companies. As an investor, Brian believes anything is possible.
Dan Meyers has led over 40 clinical studies ranging from first-in-human Phase 1 studies to pivotal Phase 3 and post-approval programs. As a Senior Translational Medicine Expert at Novartis, he chaired the scientific review committee for all general medicine studies within NIBR. More recently, Dan served as head of product development for the Janssen Human Microbiome Institute. Dan brings a clinician's expertise in evaluating the translational potential of early-stage assets.
Michael Serrano-Wu has been a key driver for several first-in-class drug discovery efforts. At BMS, he broke open the nascent field of HCV NS5A-targeted therapy by designing the first palindromic inhibitor of viral replication. This led to the discovery of daclatasvir and catalyzed the approval of numerous other HCV NS5A inhibitors. Later at Novartis, he led the team which discovered pradigastat, a DGAT1 inhibitor which advanced to Ph3 clinical investigation. Mike's strength as an investor stems from an ability to think outside the box.